ACNN.F Stock Overview
AusCann Group Holdings Ltd engages in the development and commercialization of cannabinoid-derived therapeutic products for humans and animals in Australia and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
AusCann Group Holdings Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.0049 |
| 52 Week High | AU$0.11 |
| 52 Week Low | AU$0.0007 |
| Beta | 0.73 |
| 1 Month Change | -69.10% |
| 3 Month Change | 42.03% |
| 1 Year Change | 36.11% |
| 3 Year Change | -94.79% |
| 5 Year Change | -98.30% |
| Change since IPO | -97.20% |
Recent News & Updates
Recent updates
Shareholder Returns
| ACNN.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -77.7% | -3.2% | -3.5% |
| 1Y | 36.1% | 11.7% | 20.2% |
Return vs Industry: ACNN.F exceeded the US Pharmaceuticals industry which returned 11.3% over the past year.
Return vs Market: ACNN.F exceeded the US Market which returned 20.9% over the past year.
Price Volatility
| ACNN.F volatility | |
|---|---|
| ACNN.F Average Weekly Movement | 955.7% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ACNN.F's share price has been volatile over the past 3 months.
Volatility Over Time: ACNN.F's weekly volatility has increased from 514% to 956% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | n/a | auscann.com.au |
AusCann Group Holdings Ltd engages in the development and commercialization of cannabinoid-derived therapeutic products for humans and animals in Australia and internationally. Its principal product includes the novel tetrahydrocannabinol and cannabidiol (THC/CBD), a powder-based hard-shell capsules based on AusCann’s Neuvis platform for the treatment of pain and related indications. The company is also involved in the research and development of medicinal cannabis.
AusCann Group Holdings Ltd Fundamentals Summary
| ACNN.F fundamental statistics | |
|---|---|
| Market cap | US$11.29m |
| Earnings (TTM) | -US$9.44m |
| Revenue (TTM) | US$1.36m |
0.0x
P/S Ratio0.0x
P/E RatioIs ACNN.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACNN.F income statement (TTM) | |
|---|---|
| Revenue | AU$1.36m |
| Cost of Revenue | AU$241.86k |
| Gross Profit | AU$1.12m |
| Other Expenses | AU$10.56m |
| Earnings | -AU$9.44m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.021 |
| Gross Margin | 82.23% |
| Net Profit Margin | -693.75% |
| Debt/Equity Ratio | 0% |
How did ACNN.F perform over the long term?
See historical performance and comparison